drug · antibody
afimkibart
Phase 3updated 5mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
indications
indications
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
Trials studying afimkibart
- phase2A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
- phase1An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
- phase2An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis
- phase3A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
- phase3A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
- phase2A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
- phase3A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
- phase3A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
News(2)
- Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b missThe anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…biospace · 1mo ago
- Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trialsA phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…fiercebiotech · 1mo ago
Data sources
last refreshed 54m ago
Found something off?
comments(0)
5-min edit window · permanent after that